Evidence: historical governance case. Imported from the supplied 65-Case Master Edition, dated September 19, 2026. Source links and classifications are retained as an attributed case account; import is not an independent source review.

Case at a glance

Case number
016
Date / range
2003
Sector
Consent, ownership, and biospecimens
Genetic asset
Canavan research samples, pedigrees, and discovery rights
Security principle
Participant Contribution and Commercialization Drift

Event summary

Greenberg v. Miami Children's Hospital illustrates how families can contribute samples, pedigrees, money, and organizing labor to research, yet later contest patenting, licensing, and access decisions surrounding the resulting genetic test.

Source: pubmed.ncbi.nlm.nih.gov — Greenberg v. Miami Children's Hospital source 1.

Source: Court opinion — Greenberg v. Miami Children's Hospital.

The case in context

Families affected by Canavan disease contributed more than specimens. Their organizing, pedigrees, and support helped make research possible. The later dispute over patenting and licensing exposed a gap between participation in discovery and authority over its commercial use.

Legal claims and their disposition need to be distinguished from the contributors' expectations. Participation does not automatically establish ownership of a discovery, but that does not make expectations about access irrelevant. Research governance can address future licensing and benefit sharing before a result becomes valuable, when the parties still have an opportunity to clarify their commitments.

Acquisition and processing

community organizing and donations → samples/pedigrees → gene discovery → patent/licensing → access and price conflict → litigation/settlement

The sequence of events

  1. community organizing and donations
  2. samples/pedigrees
  3. gene discovery
  4. patent/licensing
  5. access and price conflict
  6. litigation/settlement

What became inferable or exposed

Canavan research samples, pedigrees, and discovery rights

Greenberg v. Miami Children's Hospital illustrates how families can contribute samples, pedigrees, money, and organizing labor to research, yet later contest patenting, licensing, and access decisions surrounding the resulting genetic test.

Security dimensions

Confidentiality

The confidentiality question concerns canavan research samples, pedigrees, and discovery rights. Exposure and further inference must be distinguished from the fact of collection or availability.

Integrity

The integrity question is whether the described material, permissions, processing, or interpretation can be relied upon. Participant Contribution and Commercialization Drift identifies the particular boundary examined here.

Availability

Access and continuity are assessed for the described event; potential effects are not presented as confirmed outages or losses.

Provenance

The relevant chain follows canavan research samples, pedigrees, and discovery rights through the stages shown below. Missing public detail is not proof that internal records did not exist.

GeneticSecurity.org analysis

Genetic Exposure Radius

Not assessed

No single level is assigned where the supplied dossier gives a range, conditional outcome, or broad institutional consequence. The affected parties and proposed assessment are shown separately.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Genetic Persistence Risk

Not assessed

Persistence depends on the specific biological material or information retained. A potential effect is not treated as an observed genomic disclosure.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Genetic Provenance Integrity

Not assessed

A numeric provenance level is not inferred from the existence of a source or court record. It requires evidence of the relevant custody and processing controls.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Proposed classification and its limits

Suggested GER: GER-4 because a rare-disease community was affected. Suggested GPR: GPR-4. Suggested GPI: GPI-3/4 for well-documented research lineage.

These are proposed classifications from the supplied case dossier. Conditional scores describe an assumed exposure; they are not evidence that it occurred. A single numeric value is left unassigned when the asset or outcome is not sufficiently bounded.

What this case does not prove

It does not mean research participants automatically own discoveries or patents. It does show why contribution, expectations, and downstream control must be made explicit.

Mitigations and lessons

  • Community advisory structures
  • Benefit-sharing terms
  • Access and licensing commitments
  • Participant-facing commercialization disclosures
  • Contributor provenance
  • Post-discovery governance

Primary sources

Secondary sources

No additional source listed. See the evidence notes for limitations.

Policy and standards

Genetic Security Policy and Standards

Review and correction history

Source edition: September 19, 2026. Imported case account; no substantive corrections recorded.

Correction policy and log

Cite this case

GS-CASE-016. Greenberg: When Patient Families Helped Build a Genetic Discovery. GeneticSecurity.org. https://geneticsecurity.org/cases/016-greenberg-canavan-gene-commercialization/